TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects, ages 18-80 years, of all racial and ethnic origins.~2. Non-English Spanish speakers will be included in the study.~3. We are recruiting 12 patients with thermal burn injuries (percent total body surface area burned \>/= 20%). Patients will be at least five days from the date of the burn injury.~4. Patients will have central venous or arterial line access.~5. Patients will be already be receiving standard of care antimicrobial therapy for a suspected infection.~Exclusion Criteria:~1. Pregnant or nursing or unwilling to use a reliable contraception method during the study. The effects of ceftolozane and tazobactam on pregnancy are unknown. In addition, the metabolic changes that accompany pregnancy may alter the concentration-time profile of ceftolozane and tazobactam, so that the pregnancy and post-partum state would be a confounding variable.~2. Abnormal liver function tests: transaminases \>10 times upper limit of normal, Alkaline phosphatase \>5 times upper limit of normal, total bilirubin \>5 times upper limit of normal.~3. History of allergies to beta-lactam antibiotics.~4. Patients unwilling to comply with study procedures.~5. Current or previous participation within 28 days of enrollment in another research study that involves the use of medication, contrast, or any other compound that may alter blood count and/or blood chemistry (liver function, kidney function or electrolyte balance), unless waved by principal investigator (PI).~6. Donation of 450mL (one unit) of blood or more within 8 weeks (56 days) prior to study enrollment, unless waved by PI.~7. Creatinine clearance \< 30 ml/min as estimated by the Cockcroft-Gault equation.~8. Patients who are receiving piperazillin/tazobactam or have received piperacillin/tazobactam within the past 48 hours.~9. Patients who are receiving vasopressors.~10. Patients with a total body weight \< 60 kg or \> 130 kg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ceftolozane/tazobactam (Type: EXPERIMENTAL): One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Global Shoulder Concept (GSC) Method Versus Classic Physical Therapy for Shoulder Tendinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* painful, chronic tendinopathy (more than 3 months) of the rotator cuff, confirmed by MRI~Exclusion Criteria:~* The patient is pregnant or breastfeeding~* Any emergency situation~* Non-mechanical tendinopathies (metabolic, neurological, capsulitis, reflex sympathetic dystrophy) and tendon surgery (tendon surgery and acromioplasty)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- GSC physcial therapy (Type: EXPERIMENTAL): Patients included in this arm of the study will follow the Global Shoulder Concept physical therapy sequence.
- Standard (Type: ACTIVE_COMPARATOR): Patients in this arm of the study will follow the standard physical therapy sequence.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with multiple sclerosis (MS) with neurogenic detrusor overactivity proven by urodynamics~* Stable MS with an Expanded Disability Severity Score (EDSS) less than or equal to 6.5~* Voluntary micturitions~* Number of micturitions \> 8 per day, with or without episodes of urgency and urgency incontinence~* Signed informed consent form~Exclusion Criteria:~* Pregnancy, breastfeeding~* Patients requiring self-catheterizations~* Patients unable or unwilling to learn self-catheterisation~* Recent (\<12 weeks) or current treatment with botulinum toxin for any non-urological indication~* Recent (≤ 8 weeks) or current treatment with anticholinergic drugs~* Patients with a positive history or evidence of pelvic / urological abnormality (interstitial cystitis, bladder lithiasis in the 6 months preceding the screening, or any other condition / operation affecting the bladder or prostate)~* Any contraindication to Vesicare®:~  * Hypersensitivity to the active ingredient or to one of the excipients~ * Urinary retention~ * Untreated narrow-angle glaucoma~ * Severe gastrointestinal illness (e.g. toxic megacolon)~ * Myasthenia gravis~ * Severe hepatic failure~ * Hemodialysis~ * Severe renal failure, or liver function disturbances of moderate severity with concomitant treatment with a strong inhibitor of the CYP3A4 isoenzyme, including patients at risk for these diseases.~* Any contraindication to BOTOX®:~  * Known hypersensitivity to the active substance or to one of the excipients~ * Presence of a symptomatic infection at the planned injection site(s)~ * Urinary tract infection at the time of planned treatment~ * Patients who present with acute urinary retention at the time of treatment and who do not regularly use bladder catheterization~ * Patients who do not want and / or cannot, if necessary, perform self-intermittent catheterisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vesicare (Type: ACTIVE_COMPARATOR): Group 1: will be treated with an anticholinergic (Vesicare® 10 mg per day for 12 weeks)
- Botox (Type: ACTIVE_COMPARATOR): Group 2: will receive an intra-detrusor injection of a low dose of botulinum toxin type A (100 U of BOTOX®).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* elective cesarean delivery~* planned spinal anesthesia~Exclusion criteria:~* Non-English speaking~* Urgent or emergent cesarean delivery~* Active labor \[defined as: \>4cm cervical dilation or regular contractions noted on tocometer (\>2 contractions in a 10 minute period for 30 consecutive minutes)\]~* Chronic antepartum opioid use~* History of substance abuse (alcohol or drug)~* Current tobacco use~* Chronic steroid use

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- bupivacaine 0.25% (Type: ACTIVE_COMPARATOR): standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25%
- bupivacaine 0.25% + epinephrine (Type: ACTIVE_COMPARATOR): standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25% with Epinephrine
- Saline Solution (Type: PLACEBO_COMPARATOR): standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous NACL 0.9% (placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Descartes-30 in Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years of age or older at the time of enrollment~* Patient maintains a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS~Exclusion Criteria:~* Patient is currently enrolled into another therapeutic clinical trial with an experimental therapy that has not received marketing approval by U.S. FDA.~* Patient is in moribund state with expected survival \<24 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Descartes 30 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Osteopathic Intervention in Professional Handball Players

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male and female International players who are part of the French Handball team~Exclusion Criteria:~* history of thoracic or diaphragmatic surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- experimental (Type: EXPERIMENTAL): The intervention evaluated is a technique of prolonged abdominal manual pressure centered on the zone of restriction of mobility called trigger point with diaphragmatic aim.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Range Finding Study for MK0893 (0893-008)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have Type 2 Diabetes Mellitus, with suboptimal glucose control, while either not on AHA (antihyperglycemic agent) therapy or on monotherapy or on low-dose combination therapy~Exclusion Criteria:~* Patients have a history of Type 1 Diabetes Mellitus~* Patients taking insulin or thiazolidinedione (TZD, a peroxisome proliferator-activated receptor \[PPAR\]-gamma agonist)~* Patients who have a contraindication to metformin

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MK0893 80 mg (Type: EXPERIMENTAL): MK0893 tablets totaling 80 mg once daily.
- MK0893 60 mg (Type: EXPERIMENTAL): MK0893 tablets totaling 60 mg once daily.
- MK0893 40 mg (Type: EXPERIMENTAL): MK0893 40 mg tablet once daily.
- MK0893 20 mg (Type: EXPERIMENTAL): MK0893 20 mg tablet once daily.
- Metformin (Type: ACTIVE_COMPARATOR): Metformin HCL 500 mg tablet twice daily BID titrating up to 1000 mg twice daily over 3 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): PLA tablets. 12 week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Trabeculectomy With Ologen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary open-angle glaucoma with progression of visual field loss and/or uncontrolled intraocular pressure levels with medication.~* Indication for trabeculectomy with mitomycin-C~Exclusion Criteria:~* Unability to discontinue oral anticoagulants~* Difficulty in reading or speaking Dutch~* Previous ocular surgery (cataract surgery allowed)~* Pregnant and breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ologen implantation (single arm) (Type: EXPERIMENTAL): Ologen implantation as an adjunctive to trabeculectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or females between the ages of 18 to 65 years of age.~* Documented diagnosis for the metabolic syndrome:~* Subjects with hypertension (SP\>130mmHg)~* Subjects with central obesity (females waist \>35; males waist \>40)~* Subjects with dyslipidemia (HDL \<40mg/dl, triglycerides \> 150 mg/dl)~* Subjects who are insulin resistance (fasting glucose \>100mg/dl)~Exclusion Criteria:~* Subjects who smoke~* Women who are pregnant (confirmed by urine beta-HCG).~* Women who are breast feeding~* Subjects with documentation of the following health risk:~  * Subjects with serum creatinine \>2.0 mg/dl (males), \>1.8 mg/dl (females)~ * Subjects whose creatinine clearance \< 50 mls/min~ * Subjects with serum potassium \>5.5mEql~ * Subjects with Type 2 diabetes with microalbuminuria (spot urine protein/creatinine ration \>0.2)~* Subjects who are currently taking the following medications:~* Warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: ACTIVE_COMPARATOR): Eplerenone (study drug)
- Treatment B (Type: ACTIVE_COMPARATOR): Ramipril

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Stenting Versus Surgical Bypass for Low Bile Duct Obstruction by Cancer of the Pancreatic Head

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal or greater than 18 years~* Diagnosis of unresectable cancer of the pancreatic head (after clinical, laboratory, radiological assessment) requiring palliative treatment for biliary obstruction. In unclear cases an exploratory laparotomy will be performed and resectability will be evaluated intraoperatively~* Operability certified by anesthesiologist~* Written informed consent~Exclusion Criteria:~* Intervention technically/medically not feasible~* Expected lack of compliance~* One treatment option considered to be clearly in favor of the patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
- B (Type: ACTIVE_COMPARATOR): Endoscopic biliary stenting using metal stent (completed by duodenal stent, if necessary)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oxygen Therapy in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children ≥ 6 years and adults ≥ 18 years with CF in a stable state~* With a forced expiratory volume in one second (FEV1) ≤ 50% of predicted value~* Having a pulse oximetry (SpO2) in room air ≤ 90% for ≥ 10% of the night and/or a SpO2 ≤ 90% for ≥ 10 minutes during the night~* Any patient with prior noninvasive positive pressure ventilation (NPPV) but who has stopped NPPV at least 15 days before the start of the study.~* Written approval by the patient and by the parents in case of a pediatric patient~* Patient having the French social security coverage~Exclusion Criteria:~* Patients with a respiratory exacerbation during the last 15 days~* Patients with NPPV or long term oxygen therapy prior to the start of the study and unable to stop this treatment~* Impossibility of a medical examination~* Pregnant patient or breastfeeding patient

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Air - oxygen (Type: OTHER): One period in room air and one period with nocturnal oxygen therapy, separated by a wash out period of 2 to 6 weeks.
- Oxygen - Air (Type: OTHER): One period with nocturnal oxygen therapy and one period in room air, separated by a wash out period of 2 to 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Validate a Computerized Neuropsychological Test Battery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 60-80~Exclusion Criteria:~* Neurological disorder that results in motor or cognitive dysfunction~* Perceptual or motor difficulties that would prevent subjects from taking the assessment~* MMSE score \<20~* MoCA score \<26~* MAS score \>9~* Significant abnormal neurologic examination findings

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18 years or older - Complicated skin and skin structure infection (cSSTI) - Infection of sufficient severity to warrant hospitalization - Infection of sufficient severity such that it is expected to require at least 5 days of intravenous antibiotic therapy. patients must have a positive culture for MRSA that has been obtained from the skin infection site and/or blood samples at any time within the 72hrs before the first dose.~Exclusion Criteria:~* Received systemic antibacterial drugs for greater than 24 hours within 96 hours prior to first dose of study drug - Uncomplicated skin and skin structure infections, skin infections suspected to be caused by viral or fungal pathogens - Diabetic foot infections, decubitus ulcers, ulcers due to peripheral vascular disease - Infection caused by human or animal bites, sternal wound infections, bone infection or arthritis due to an infection, critical limb ischemia of the affected limb - Chronic liver disease or severe impaired renal function, severe low white blood cell count, burns on greater than 15% of total body surface area, necrotizing skin infection, amputation required of primary site of infection, sustained shock

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Ceftaroline fosamil (Type: EXPERIMENTAL): Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
- Vancomycin plus aztreonam (Type: ACTIVE_COMPARATOR): Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues